SCORE2 Study for Retinal Vein Occlusion

SCORE2 Study for Retinal Vein Occlusion

People with a retinal vein occlusion experience macular edema (swelling in the center of the retina, the thin light-sensitive tissue at the back of the eye) from blockage in a large retinal vein. This blockage is called a central retinal vein occlusion (CRVO). Retinal veins drain blood away from the retina back to your heart. A blockage in one of the large retinal veins (central retinal vein occlusion-CRVO) can result in fluid in the center of the retina (macular edema). This can result in decreased vision in that eye.

This research study will compare the drugs Eylea® (aflibercept) and Avastin® (bevacizumab) for treatment of macular edema due to CRVO. Eylea is a drug that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of macular edema due to CRVO. Avastin is a drug that has been approved by the FDA for the treatment of some types of cancer but it has not been approved for use in the eye. However, since 2006, Avastin has been used to treat a wide variety of eye problems, including CRVO. Avastin interferes with the growth of new vessels and prevents leakage of fluid from new blood vessels. Both Eylea® and Avastin® are proteins made in a laboratory and are thought to decrease the macular edema by decreasing the activity of vascular endothelial growth factor (VEGF) in the eye. Thus, these drugs are known as anti-VEGF drugs and are given via injections into the eye.

A total of about 360 people are expected to participate in this study nationally, including up to 10 at the Medical College of Wisconsin/Froedtert Hospital.

Participant Eligibility

Potential participants may qualify for the study if they meet all of the inclusion criteria and none of the exclusion criteria.

Inclusion Criteria
Macular edema (swelling) due to a blocked vessel (CRVO) (will be verified by SCORE2 study doctor).
Aged 18 years or older.

Exclusion Criteria
Laser treatment for macular edema within 3 months.
Steroid injection in your eye for macular edema within 4 months.
Anti-VEGF injection in your eye for macular edema within 2 months.
Major eye surgery (including cataract surgery) within 4 months.
Problems with your eyes due to diabetes.

Contact

Katie McKenney
(414) 955-7866
kmckenney@mcw.edu

Additional Study Details
Full Study Title
Study of Comparative Treatments for Retinal Vein Occlusion 2: A Multicenter, Prospective, Randomized, Phase III, Non-Inferiority Trial of Eye with Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks versus Intravitreal Aflibercept Every 4 Weeks

Study ID: NCT01969708

Principal Investigator(s)
Dr. Judy Kim, M.D.

Study Sites
Medical College of Wisconsin- The Eye Institute